Ignite Creation Date:
2024-05-06 @ 4:10 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04898647
Status:
RECRUITING
Last Update Posted:
2023-02-10
First Post:
2021-05-17
Brief Title:
Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
Sponsor:
Centre Hospitalier Universitaire Amiens
Organization:
Centre Hospitalier Universitaire Amiens
Study Overview
Official Title:
Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SLPRaresHvisc
Brief Summary:
Walsdenström Macroglobulinemia WM is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M IgM in blood Clinical manifestations of the hyperviscosity syndrome HVS are related to the large amount of IgM in circulating blood or to some physicochemical characteristics such as the presence of a cryoglobulin property Although HVS is one of the most frequent criteria for initiating therapy in WM few studies focused on its description and no diagnostic criteria are available
The present study aims to identify a diagnostic system for HVS taking into account objective symptoms such as bleedings fundoscopic findings and also subjective symptoms such as fatigue and comorbidities that may influence the severity of symptoms
The present study aims to identify a diagnostic system for HVS taking into account objective symptoms such as bleedings fundoscopic findings and also subjective symptoms such as fatigue and comorbidities that may influence the severity of symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None